Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: APDS Clear all
Terminated Phase 2Phase 3 Interventional Results available

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02859727
View directory record Official record
Conditions
Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Interventions
CDZ173
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous
Interventions
RP6530
Drug
Lead sponsor
Rhizen Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Duarte, California • Orange, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

NCT00083408
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pamidronate, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2010 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02435173
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Atorvastatin (Lipitor) to Prevent Bone Pain

NCT00120133
View directory record Official record
Conditions
Osteoporosis
Interventions
Atorvastatin
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Pilot Trial of IV Pamidronate for Low Back Pain

NCT01210599
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pamidronate
Drug
Lead sponsor
Pappagallo, Marco, M.D.
Individual
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Pamidronate to Treat Osteogenesis Imperfecta in Children

NCT00005901
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Pamidronate (Aredia)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

NCT02164006
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
TGR-1202 + brentuximab vedotin
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Duarte, California • San Diego, California • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 25, 2026, 4:47 PM EDT
Suspended Phase 1Phase 2 Interventional

Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC

NCT03428295
View directory record Official record
Conditions
Glucose, Low Blood, Glucose, High Blood
Interventions
Dose Safety AP system
Device
Lead sponsor
Dose Safety Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 25, 2026, 4:47 PM EDT
Not listed Phase 1 Interventional

A Pilot Trial of Intravenous (IV) Pamidronate for Low Back Pain

NCT00101790
View directory record Official record
Conditions
Low Back Pain
Interventions
pamidronate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Bisphosphonate Treatment of Osteogenesis Imperfecta

NCT00063479
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Zoledronic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
10
States / cities
Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

NCT00124605
View directory record Official record
Conditions
Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pamidronate disodium, arsenic trioxide, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cisplatin, Doxorubicin, Methotrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide

NCT00083382
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pamidronate, Thalidomide, Zometa
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 25, 2026, 4:47 PM EDT
Active, not recruiting Phase 3 Interventional

Pediatric Patients Aged 1 to 6 Years With APDS

NCT05693129
View directory record Official record
Conditions
APDS
Interventions
Leniolisib
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
1 Year to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Shaker Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT02100852
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
TGR-1202 + Obinutuzumab + Chlorambucil
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Huntsville, Alabama • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional

Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain

NCT00482378
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm, Pain
Interventions
Pamidronate, Zoledronic acid, Sm 153 lexidronam
Drug · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of the Use of ME-APDS During Colonoscopy

NCT04640792
View directory record Official record
Conditions
Screening Colonoscopy, Surveillance Colonoscopy
Interventions
Screening or Surveillance Conventionall colonoscopy
Procedure
Lead sponsor
Magentiq Eye LTD
Industry
Eligibility
18 Years to 90 Years
Enrollment
952 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 25, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

NCT02742090
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Huntsville, Alabama • Washington D.C., District of Columbia • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 25, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collecting Recorded Videos of Colonoscopy Tests

NCT03937063
View directory record Official record
Conditions
Colon Polyp
Interventions
Collecting recorded videos of Colonoscopy screening tests
Other
Lead sponsor
Magentiq Eye LTD
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 25, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

NCT01875458
View directory record Official record
Conditions
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

NCT00004088
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, melphalan, pamidronate disodium, thalidomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 25, 2026, 4:47 PM EDT
Completed Not applicable Interventional

Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation

NCT00302627
View directory record Official record
Conditions
Transplant Bone Disease
Interventions
Pamidronate, vitamin D, Calcium Carbonate
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 25, 2026, 4:47 PM EDT